15-09-2009 16:27 How can we harness the power of stem cells to repair the heart or other damaged organs? Dr.

Continued here:
Stem Cell Therapy in Cardiac Disease - Video

27-10-2006 00:42 The story of living with the horrible disease, how it affects the afflicted and their loved ones. Stem Cell research is the most promising research in terms of potential cures for this and many other currently incurable diseases.

Here is the original post:
Living With Alzheimer's Disease - Video

22-09-2011 18:30 http://www.StemCellTreatment.org is the leading stem cell treatment center in the world. Using the latest technology and research, the American Stem Cell Treatment

See more here:
Stem Cell Treatment - Video

HAWAII KAI (HawaiiNewsNow) -

Cutting-edge technology is helping Hawaii's pets live better lives for months, even years. We were there as a beloved dog named Kumba received one of the first-ever, in-clinic stem cell therapy surgeries in the islands.

13 year old Kumba doesn't know he's a guinea pig. The Rottweiler-Lab mix is one of the first in Hawaii to undergo the stem cell procedure at Surf Paws in Hawaii Kai.

Kumba suffers severe arthritis in his hips and knees, doesn't eat much, and is even a bit depressed. "It's an effort for him to get up off the floor, and when he gets up and crosses the room, you can see the stiffness," says his owner, Rumi Hospodar.

Kumba's kids learn some of details of his surgery. Then, he's moved to a table and nods off from anesthesia. Once he's prepped, the procedure begins. The vet removes about two tablespoons of fat tissue from Kumba's shoulder. From there, the stem cells are separated from the fat and activated. Then, they're injected back into the affected areas.

The entire process takes four hours, but the dog is actually only under for about 20 minutes. Surf Paws used to send the tissue to the mainland for processing, but with technology from Medi-Vet America, they can do it all here.

"The patient had to be, you know, go home and come back a few days later and the timing was a little bit difficult. Now, everything is same day," says Surf Paws veterinarian Dr. Cristina Miliaresis.

Cost depends on the size of animal but can run up to $2,800. It's mainly done on dogs, cats, and horses who suffer osteoarthritis, hip dysplasia, ligament and cartilage damage, and other degenerative diseases. Their quality of life can improve within a couple of weeks.

Dr. Miliaresis says, "Some people might say, 'Oh, the dog's 13. Why are you doing this for a 13 year old dog? But even 6 months, pain-free, after a very, it's not simple, but it's a pretty straightforward procedure, to me (would be) just amazing."

The techs move all 97 pounds of Kumba to post-op - while his anxious owner looks on.

See the article here:
Stem cell therapy in Hawaii going to the dogs

September 08, 2012 10:01 PM

A Brownsville man admitted to charging a couple more than $8,000 to perform an unapproved stem-cell procedure on their child who had experienced neurological problems after nearly drowning.

Francisco Morales, 52, has pleaded guilty to a conspiracy to introduce misbranded and unapproved drugs into interstate commerce, U.S. Attorney Kenneth Magidson announced Friday.

Lawrence Stowe, 59, of Illinois, pleaded guilty to the same charges.

These pleas are a victory for the American public, in demonstrating the FDAs commitment to investigating cases of individuals and businesses that prey on the sick and vulnerable with phony medical treatments, said Patrick J. Holland of the Food and Drug Administrations Office of Criminal Investigations.

Alberto Ramon, 50, of Del Rio, and Vincent Dammai, 42, of Mount Pleasant, S.C., are also charged in the case and will go to trial in late November.

Magidson said in a press release that Morales and Stowe both falsely represented that they were licensed to practice medicine and that they each operated medical clinics in Brownsville.

In January 2006, Stowe admitted that he started using Stowe BioTherapy Inc. and The Stowe Foundation to advertise and promote a medical treatment protocol for several neurological diseases that have no cures.

The treatment was called Applied Biologics and consisted of supplements, vaccines, patient specific transfer factors and stem cell therapy. Stowe told patients that the FDA reviewed the treatment and considered it effective for Lou Gehrigs disease, MS and Parkinsons. There are no cures for these diseases.

Stowe and Morales pleaded guilty to introducing an unapproved drug called Immune Factor G-40, and Stowe further admitted that he introduced an unapproved treatment called patient specific transfer factors.

View original post here:
Details revealed in complicated stem-cell case

Source:
http://www.longevitymedicine.tv/feed/

Public release date: 6-Sep-2012 [ | E-mail | Share ]

Contact: Tom Vasich tmvasich@uci.edu 949-824-6455 University of California – Irvine

Irvine, Calif., Sept. 6, 2012 Efforts to begin human clinical trials using stem cells to treat Alzheimer’s disease and retinitis pigmentosa received a $37.3 million boost from the California Institute for Regenerative Medicine during its most recent round of funding on Sept. 5.

UC Irvine scientists will be part of two research teams garnering CIRM Disease Team Therapy Development Awards, which are designed to accelerate collaborative translational research leading to human clinical trials. In one, Dr. Henry Klassen, an associate professor of ophthalmology in UC Irvine’s Sue & Bill Gross Stem Cell Research Center, and his collaborators at UC Santa Barbara and Cedars-Sinai Medical Center, received $17.3 million to cultivate therapeutically potent retinal progenitor stem cells to treat the blinding effects of retinitis pigmentosa.

In the other, StemCells, Inc. in Newark, Calif., received $20 million and will collaborate with Frank LaFerla and Mathew Blurton-Jones neurobiologists with the stem cell research center and the Institute for Memory Impairments and Neurological Disorders (UCI MIND) to advance research using the company’s proprietary purified human neural stem cells to improve memory in people with Alzheimer’s disease.

“CIRM’s support for UC Irvine’s efforts to advance stem cell-based treatments for a variety of diseases is extremely gratifying,” said Peter Donovan, director of the Sue & Bill Gross Stem Cell Research Center. “Henry’s work on retinitis pigmentosa and Frank and Mathew’s on Alzheimer’s disease hold great promise, and we are delighted that they have the support to see their work move toward the clinic.”

Klassen’s objective is to introduce stem cells that rescue and reactivate damaged and dying photoreceptor rods and cones, thus reversing the course of RP even at relatively advanced stages. The current CIRM funding will allow Klassen and his collaborators to grow these cells under conditions ensuring that pharmaceutical standards are met. The resulting cells will be tested in animals for safety and to make certain that they are therapeutically potent. Then the team will seek FDA approval for the use of these cells in early clinical trials, in which a small number of patients with severe RP will be injected with cells in their worse-seeing eye and followed clinically for a specified period of time to determine the safety and effectiveness of the treatment.

“We believe it’s possible to rejuvenate a clinically significant number of cones in the degenerating retina,” said Klassen, whose work also has received long-standing support from the Discovery Eye Foundation. “Our methods have been validated, and I’m optimistic that stem cell-based treatments can help restore fading vision in people with eye diseases.”

The CIRM award will further LaFerla and Blurton-Jones’s efforts with StemCells, Inc. to understand how human neural stem cells can treat Alzheimer’s disease, the leading cause of dementia in the U.S. Earlier this year, the researchers reported findings showing that neural stem cells restored memory and enhanced synaptic function in two animal models relevant to Alzheimer’s disease, possibly by providing growth factors that protect neurons from degeneration. With these studies establishing proof of concept, the team intends to conduct further animal studies necessary to seek FDA approval to start testing this therapeutic approach in human patients.

“Our goal is to research ways to make memories last a lifetime, and we’re excited to investigate the potential efficacy of stem cells for Alzheimer’s disease,” said LaFerla, the UCI MIND director and Chancellor’s Professor and chair of neurobiology & behavior.

Read more from the original source:
State stem cell research funding agency awards $37.3 million to aid UC Irvine efforts

Source:
http://www.longevitymedicine.tv/feed/

Public release date: 22-Jun-2012 [ | E-mail | Share ]

Contact: William Gilroy gilroy.6@nd.edu 574-631-4127 University of Notre Dame

Alumnus Michael Gallagher and his wife, Elizabeth, have made a $5 million gift to establish the Elizabeth and Michael Gallagher Family Professorships in Adult Stem Cell Research at the University of Notre Dame.

Their gift, which will fund three new endowed professorships in adult and all forms of non-embryonic stem cell research, will strengthen Notre Dame's leadership in the field of stem cell research and enhance the University's effective dialogue between the biomedical research community and the Catholic Church on matters related to the use and application of stem cells and regenerative medicine.

"As a Catholic university, Notre Dame carries a mantle of responsibility to use our scholarship and resources to help alleviate human suffering, and, in this area of research in particular, to do so with deep respect for the sanctity of all human life," said Rev. John I. Jenkins, C.S.C., the University's president. "These new professorships will enable us to effectively build upon an already strong foundation in this critically important field. We are tremendously grateful to the Gallaghers for making this possible with their transformative gift."

Despite years of research, there are no known cures for a large number of degenerative diseases, such as Type 1 diabetes, Parkinson's disease, cardiovascular disease, macular degeneration and spinal cord injuries. Stem cell research has the potential to contribute to the discovery of new and successful treatments for these and other diseases because it holds the unique promise of regenerating damaged cells and tissues, fully restoring tissues and organs to their normal function.

Although this vital area of research could accelerate the ability to alleviate much human suffering, it has generated extensive ethical debate with the use of embryonic versus non-embryonic stem cells. The Catholic Church affirms the dignity of all human life at every stage and vigorously opposes the destruction of human embryos for the harvesting of stem cells. At the same time, the Church strongly endorses the use of adult and non-embryonic stem cell research as a potential therapy for individuals suffering from these debilitating diseases. Research has demonstrated that adult stem cells, including all forms of non-embryonic stem cells, such as induced pluripotent stem cells and umbilical cord stem cells, can be harvested and programmed to achieve pluripotency the same characteristic that enables embryonic stem cells to differentiate into any type of cell.

An urgent need exists to increase the number of faculty experts performing adult stem cell research at Notre Dame. Doing so will expand upon the strong foundation the College of Science holds in these areas and will help create an environment for excellence in which faculty and students can learn, grow, collaborate and ultimately affect human health.

"We are overwhelmed with gratitude at the generous gift from Mike and Liz Gallagher," said Gregory P. Crawford, dean of the College of Science. "The impact of this gift is truly beyond measure. It will play a crucial role in attracting three more of the best faculty in the field of adult stem cell research to Notre Dame. Furthermore, this gift will equip our existing talented group of adult stem cell researchers at Notre Dame to take the next great leap toward ultimately forming a premier center in adult stem cell research."

Michael Gallagher is a 1991 graduate of Notre Dame, and his wife, Elizabeth, is a 1992 graduate of Saint Mary's College. They have two sons, Brock and Jack, and currently live near Denver.

Excerpt from:
Notre Dame establishes professorships in adult stem cell research

Newswise Troy, N.Y. Ground-breaking research to advance the application of stem cells to address critical injuries and diseases will be taking place at Rensselaer Polytechnic Institute, in a new center funded by New York state and opened today (June 22, 2012).

The Rensselaer Center for Stem Cell Research was launched officially by Rensselaer President Shirley Ann Jackson, New York State Department of Health Commissioner Nirav Shah, and Jonathan Dordick, director of the Rensselaer Center for Biotechnology and Interdisciplinary Studies (CBIS) and the Howard P. Isermann 42 Professor of Chemical and Biological Engineering. They were joined at the ribbon cutting by Glenn Monastersky, CBIS operations director and biomedical engineering professor of practice. Monastersky is also principal investigator under the $2.45 million grant awarded to fund the new center, from the New York State Stem Cell Science Program (NYSTEM).

The opening of the Rensselaer Center for Stem Cell Research marks a milestone on the path toward this important area of exploration, which promises so much in terms of alleviating disease and improving health, said Jackson. At the center we will work at the frontiers of this promising discipline in collaboration with New York state and investigators from across the region.

This research complements stem cell research, sponsored by New York and the National Institutes of Health, that is already in progress at Rensselaer, Jackson added. Due to our commitment to biotechnology that began over 10 years ago under The Rensselaer Plan, we are able to link engineering with the life and physical sciences in ways that allow us to explore new possibilities. We are grateful to Dr. Shah and the state of New York for their leadership in this important research area, and for providing the funding to launch this center.

Governor Cuomo recognizes that stem cell research is a vital and growing industry that helps create jobs here in the Capital Region and around the state, said Nirav R. Shah, M.D., M.P.H., New York State Commissioner of Health. Targeting our investment in results-oriented research enterprises like this center will lead to medical advances as well as expand our economy and make New York the place to be for 21st century health and science research.

According to Dordick, the new center continues to place CBIS and the research conducted there on the leading edge of efforts to harness advances in biotechnology to address 21st century health challenges.

Ranging from our work on the blood anti-coagulant drug heparin to solutions to fighting some of todays super bugs to important advances in understanding Alzheimers disease, we are focusing our efforts on scientific advances that will ultimately open the doors to new cures for traumatic injuries or treatments for long-term conditions and diseases, Dordick said. Now, working with our partners at New York state and other researchers in the region, we will expand our work on stem cells to help the medical and scientific research communities advance efforts to better understand those cells and how they can be used in medicine.

Research on stem cells offers promise in an array of health areas, ranging from trying to regenerate damaged nerve cells following spinal cord injuries to offering potential cures for autoimmune diseases such as multiple sclerosis, lupus, rheumatoid arthritis, and Type 1 diabetes. According to the National Institutes of Health (NIH), stem cells are important because unlike other cells in the human body they are capable of dividing and renewing themselves for long periods. In addition, because stem cells are unspecialized meaning that they are not associated with any tissue-specific functions early research has shown that under the right circumstances these cells can give rise to cells associated with specific functions, under a process called differentiation. Today, according to NIH, scientists are just beginning to understand the so-called triggers that can start stem cell differentiation into, for example, nerve, muscle, or bone cells.

The new state-of-the-art center is housed on the ground floor of the Rensselaer biotechnology center. In addition to advanced cell biology research equipment, new lab equipment acquired with funding from New York state includes an Olympus VivaView microscopy/incubation system and a Thermo Fisher Arrayscan cell-imaging system that utilizes advanced optics and analytical software to guide the analysis of stem cell development.

The Rensselaer Center for Stem Cell Research and its associated scientific staff, will enable collaborations with several New York partners including the New York Neural Stem Cell Institute, Albany Medical College, the University at Albany, the University of Rochester Medical School, and the Trudeau Institute. The main focus of the center is the basic science critical to development of stem cell-based therapies for human diseases and traumatic injuries.

Visit link:
Rensselaer and New York State Launch New Stem Cell Research Center

22-01-2011 12:29 http://www.StemCellTreatment.org This is Zebiba Shekhia, a patient with lung disease that received stem cell treatment for lung disease at American Stem Cell and Anti-Aging Center. After receiving her stem cell treatment lung disease she is now breathing much better and feels fantasitc! Go to your website for more information and find out how ASCAAC can help you!

Read the original here:
Stem Cell Treatment Lung Disease - Video

To: HEALTH, MEDICAL AND POLITICAL EDITORS

WASHINGTON, Feb. 23, 2012 /PRNewswire-USNewswire/ -- The Stem Cell Action Coalition opposes Virginia House Bill No.1, the so-called Virginia "personhood bill." The Virginia Senate Committee on Education and Health is scheduled to take the matter up this week.

The language of the personhood bill states, in part, that the laws of Virginia "shall be interpreted and construed to acknowledge on behalf of unborn children at every stage of development all of the rights, privileges and immunities available to other persons, citizens and residents." The bill further states "unborn children shall include the offspring of human beings from the moment of conception until birth at every stage of biological development."

HB 1 arguably would apply to every aspect of Virginia law thus profoundly impacting inheritance, adoption, guardianship, civil and criminal liability by according the same rights as adults and children to a single cell.

The personhood bill would surely interfere with reproductive and related rights of women and couples along several fronts. These interferences include making it exceedingly difficult for couples in Virginia to seek in vitro fertilization as a means of creating families and donating for research IVF-created embryos not needed for implantation or not sufficiently healthy for implantation. Moreover, the law would prevent the pursuit of medical research in Virginia that utilizes human embryonic stem cells.

In this twisted new world, Virginia researchers deriving embryonic stem cells from donated embryos might be charged with capital crimes, even murder. Couples donating embryos to research might be designated as accessories to these crimes. Microscopic embryos, consisting of a few cells in lab dishes or frozen in IVF clinics might be designated as wards of the state and by mandate have legal guardians appointed on their behalf.

Human embryonic stem cell research has been described by scientists as the "gold standard" for those seeking to develop cures based on stem cell technology for many diseases and maladies such as Parkinson's, ALS, diabetes, MS, macular degeneration and other causes of blindness, spinal cord injuries, and other medical conditions for which there is no known cure.

Bernard Siegel, J.D., spokesperson for the Coalition and executive director of the Genetics Policy Institute commented, "It is a sad day indeed when the Commonwealth of Virginia should become an outpost for extremism by impeding potentially lifesaving scientific research. Thomas Jefferson would be appalled. The wise voters of Colorado (twice) and Mississippi overwhelmingly rejected personhood amendments to their state constitutions.

The profound implications of the personhood bill cannot be wished away by its sponsors. Passage of this bill would be an affront to couples trying to avail themselves of modern infertility treatments, stem cell researchers targeting cures and to all Virginians suffering from chronic and life threatening disease. Passage of HB 1 is akin to crushing hope.

Human embryonic stem cell research holds the promise of discovering the root causes of disease, serves as a tool for drug discovery, and will surely lead to regenerative medicines and cell therapies for repairing or replacing damaged tissues and organs.

Microscopic cells in a lab dish, that by a couples' decision, will never be implanted in a womb, should not be defined as 'people'," Siegel continued.

HB 1 represents a concerted move by opponents of all forms of early termination of pregnancy and medical research involving human embryos to attempt to pass laws to define "person" as the being that comes into existence at conception. In addition to Virginia, similar efforts to pass "personhood" legislation are underway in Oklahoma, Mississippi and in other states.

The Stem Cell Action Coalition has 75 nonprofit affiliated organizations including patient groups, medical philanthropies, scientific and medical societies and public interest organizations all dedicated to advancing scientifically meritorious and ethically responsible research.

The Stem Cell Action Coalition serves as an engine to unite the pro-cures community. It recognizes that human embryonic stem cell research must be a national public health priority at all branches and levels of government, not only as a matter of the medical health of the individuals who comprise the United States, but also as a matter of national financial health. The Coalition sponsors a web site http://www.stemcellaction.org and can be found on Twitter @StemCellAction and on Facebook at http://www.facebook.com/stemcellaction.

SOURCE The Stem Cell Action Coalition

-0-

More here:
Stem Cell Action Coalition Opposes Virginia Personhood Bill

Public release date: 14-Feb-2012
[ | E-mail | Share ]

Contact: Mary F. Masson
mfmasson@umich.edu
734-764-2220
University of Michigan Health System

ANN ARBOR, Mich. ? The University of Michigan's first human embryonic stem cell line will be placed on the U.S. National Institutes of Health's registry, making the cells available for federally-funded research. It is the first of the stem cell lines derived at the University of Michigan to be placed on the registry.

The line, known as UM4-6, is a genetically normal line, derived in October 2010 from a cluster of about 30 cells removed from a donated five-day-old embryo roughly the size of the period at the end of this sentence. That embryo was created for reproduction but was no longer needed for that purpose and was therefore about to be discarded.

"This is significant, because acceptance of these cells on the registry demonstrates our attention to details of proper oversight, consenting, and following of NIH guidelines established in 2009," says Gary Smith, Ph.D., who derived the line and also is co-director of the U-M Consortium for Stem Cell Therapies, part of the A. Alfred Taubman Medical Research Institute.

"It now makes the line available to researchers who can apply for federal funding to use it in their work; this is an important step."

The line is the culmination of years of planning and preparation and was made possible by Michigan voters' November 2008 approval of a state constitutional amendment permitting scientists here to derive embryonic stem cell lines using surplus embryos from fertility clinics or embryos with genetic abnormalities and not suitable for implantation.

"We expect these cells will be used by investigators worldwide to enhance our understanding of stem cell biology, and together with disease-specific lines, discover treatments and cures for genetic diseases," says Smith, who is a professor in the Department of Obstetrics and Gynecology at the University of Michigan Medical School.

U-M is among just a handful of U.S. universities creating human embryonic stem cell lines. There are only 147 stem cell lines available on the registry.

"We envision in the future that investigators will be able to use the genetically normal embryonic stem cell lines like UM4-6, together with disease-specific embryonic stem cell lines, as a model system to investigate what causes these diseases and come up with treatments," says Sue O'Shea, professor of Cell and Developmental Biology, and co-director of the Consortium for Stem Cell Therapies.

U-M also has two other human embryonic stem cells lines submitted to the national registry. Both are disease specific, the first carrying the genetic defect that causes hemophilia B, and the other carries the gene responsible for Charcot-Marie-Tooth disease, a hereditary neurological disorder.

Smith expects to soon submit eight additional human embryonic stem lines for consideration on the national registry: three genetically normal and five new disease specific lines.

This is a historic achievement that will lead to treatments and cures for serious, life-altering diseases and is more evidence that our University of Michigan researchers are leading the world in cutting-edge science that will impact health around the globe, says Eva Feldman, M.D., Ph.D., director of the A. Alfred Taubman Medical Research Institute.

"This is another major step forward for medical science in Michigan. This opens us another avenue for researchers to really begin exploring the causes and progression of those diseases, with the ultimate goal of finding new therapies for patients," says Feldman.

Contributors to the A. Alfred Taubman Medical Research Institute's Consortium for Stem Cell Therapies include the Taubman Institute; the Office of the Executive Vice President for Medical Affairs; the Office of the Medical School Dean; the Comprehensive Cancer Center; the Department of Pediatrics and Communicable Diseases; the Office of the Vice President for Research; the School of Dentistry; the Department of Pathology; the Department of Cell and Developmental Biology; the College of Engineering; the Life Sciences Institute; the Department of Neurology; and U-M's Michigan Institute for Clinical and Health Research.

A. Alfred Taubman, founder and chair of U-M's Taubman Institute, called the registry placement a tremendous step for stem cell research.

"I consider stem cells to be a modern medical miracle ? the most exciting advance in medicine since antibiotics. The progress we have made throughout the state in stem cell research has been nothing short of remarkable," says Taubman.

"This milestone means much to the University of Michigan and the state of Michigan, but also to the world. It offers another route for researchers to move ahead in studying these horrible diseases. We hope it is the first of many lines that the University of Michigan can contribute to the global efforts to improve human health."

###

For more information about the A. Alfred Taubman Medical Research Institute at the University of Michigan Medical School, visit http://www.taubmaninstitute.org

For more information about stem cell research at U-M, visit http://www.umich.edu/stemcell

[ | E-mail | Share ]

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

See original here:
U-M human embryonic stem cell line placed on national registry

15-04-2011 10:49 MIchael Yeaman, Ph.D. spoke at the "Spotlight on Devic's Disease (NMO)," an educational event presented at the CIRM Governing Board meeting on October 21, 2010. Yeaman is a professor of medicine in the Division of Infectious Diseases at the University of California, Los Angeles. Victoria Jackson, founder of the Guthy-Jackson Charitable Foundation, introduced Yeaman. The CIRM-hosted event was presented at the University of California, Los Angeles

Read more here:
Devic's Disease (NMO): Spotlight on Stem Cell Research - Michael Yeaman - Video

21-01-2011 14:02 Meet Damali and Amiel Reid, two siblings who are living with sickle cell anemia, and learn about their struggles with the disease and their hopes for a cure. Damali, 33, has started a support group for other people living with the disease, and Amiel, 16, has spent a summer learning about sickle cell by working in the lab of Dr. George Daley, Director of Stem Cell Transplantation at Children's Hospital Boston. Give patients like Damali and Amiel hope by supporting stem cell research at Children's Hospital Boston. Please visit the stem cell website stemcell101.org for more information about how you can help.

See the original post here:
Living with Sickle Cell Disease - Video

25-05-2011 10:37 (Part 2 of 7) Leeza Gibbons, member of the California Stem Cell Agency's Governing Board, gave the keynote presentation at "Synapses Firing: Connections Made", a patient advocacy event hosted by the California stem cell funding agency (CIRM). The 100+ people in attendance heard from patient advocates about living with neurodegenerative disease and from scientists about recent progress in stem cell research that may lead to new treatments. The event was held at UC-Irvine's Sue and Bill Gross Stem Cell Research Center

Excerpt from:
Leeza Gibbons: The California Stem Cell Agency's Investment in Neurodegenerative Diseases - Video

07-02-2011 13:44 Systemic lupus is associated with significant increases in premature heart attacks. Dr. Mariana Kaplan and her team at the University of Michigan Health Systems in Ann Arbor studied the abnormal function of stem cells that repair damaged blood vessels, an important factor implicated in heart disease in lupus. This study investigated the potential mechanisms by which abnormal vascular repair occurs in lupus and could contribute to designing treatments aimed at decreasing the risk of this potentially fatal complication. In this video, recorded during the 2010 American College of Rheumatology Annual Scientific Meeting in Atlanta, Georgia, Dr. Kaplan explains some of her findings, possible implications for the data she developed from the LFA funded study, and the next steps in this research.

Read more:
Endothelial Progenitor Stem Cells in Lupus Cardiovascular Disease - Video

09-06-2011 12:23 (Part 3 or 5) Jan Nolta, Ph.D., spoke at the "Spotlight on Huntington's Disease," an educational event presented at the CIRM Governing Board meeting on March 11, 2010. Nolta is director of the Stem Cell Program and Institute for Regenerative Cures at the University of California, Davis. She was introduced by Claire Pomeroy, MD, MBA The CIRM-hosted event was presented in partnership with UC Davis at the California State Capitol Building. To view the other videos in this playlists, go to: http://www.youtube.com

Here is the original post:
Huntington's Disease: Stem Cell Treatment Strategies at UC Davis - Video

12-06-2011 17:26 (Part 4 of 4) Tony Ferrandino spoke at the "Spotlight on Batten Disease," an educational event presented at the CIRM Governing Board Meeting on August 13, 2008. Ferrandino's son, Drew, was diagnosed with Batten disease in January 2007. Ferrandino spoke about his family's journey to identify Drew's condition and to seek out a treatment. Drew is enrolled in a stem cell trial being run by StemCells, Inc. To view the other videos in this playlist, go to: http://www.youtube.com

See the rest here:
Batten Disease: Spotlight on Stem Cell Research - A Father's Story - Video

10-06-2011 22:33 (Part 1 of 4) Robert Klein, JD and Leeza Gibbons, gave the welcoming remarks for the "Spotlight on Alzheimer's Disease," an educational event presented at the CIRM Governing Board meeting on December 10, 2008. Klein is Chair of the CIRM Governing Board and President of Klein Financial Corporation. Gibbons is a patient advocate member of the CIRM Governing Board and is the founder of the Leeza Gibbons Memory Foundation. The CIRM-hosted event was presented in partnership with the University of California, Irvine at the UC Irvine Student Center.

Excerpt from:
Alzheimer's Disease: Spotlight on Stem Cell Research - Leeza Gibbons - Video

23-06-2011 17:20 (Part 3 of 4) Hans Keirstead, Ph.D., spoke at the "Spotlight on Huntington's Disease," an educational event presented at the CIRM Governing Board meeting on December 12, 2007. Keirstead described strategies for using human embryonic stem cells to better understand Huntington's disease. He also explained the importance of generating highly purified human stem cell lines in a FDA-compliant manner that is scalable for future clinical use. Keirstead is co-director of the Sue and Bill Gross Stem Cell Research Center and associate professor of anatomy and neurobiology at the University of California, Irvine.

Read more from the original source:
Huntington's Disease: Spotlight on Stem Cell Research 2007 - Han Keirstead - Video

23-06-2011 16:50 (Part 4 of 4) Frances Saldana spoke at the "Spotlight on Huntington's Disease," an educational event presented at the CIRM Governing Board Meeting on December 12, 2007. Saldana spoke about the impact of Huntington's disease on her family. Saldana's daughter, a Huntington's disease patient, also spoke about the challenges of living with the disease. To view the other videos in this playlist, go to: http://www.youtube.com

See the article here:
Huntington's Disease: Spotlight on Stem Cell Research 2007 - Frances Saldana - Video